Pitfalls associated with the use of molecular diagnostic panels in the diagnosis of cryptococcal meningitis by O\u27Halloran, Jane A et al.




Pitfalls associated with the use of molecular
diagnostic panels in the diagnosis of cryptococcal
meningitis
Jane A. O'Halloran
Washington University School of Medicine in St. Louis
Alexander Franklin
Washington University School of Medicine in St. Louis
William Lainhart
Washington University School of Medicine in St. Louis
Carey-Ann Burnham
Washington University School of Medicine in St. Louis
William Powderly
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
O'Halloran, Jane A.; Franklin, Alexander; Lainhart, William; Burnham, Carey-Ann; Powderly, William; and Dubberke, Erik, ,"Pitfalls




Jane A. O'Halloran, Alexander Franklin, William Lainhart, Carey-Ann Burnham, William Powderly, and Erik
Dubberke
This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/6438
BRIEF REPORT • OFID • 1
Open Forum Infectious Diseases
B R I E F  R E P O R T
Pitfalls Associated With the Use of 
Molecular Diagnostic Panels in the 
Diagnosis of Cryptococcal Meningitis
Jane A. O’Halloran,1 Alexander Franklin,2 William Lainhart,3 Carey-Ann Burnham,3  
William Powderly,1 and Erik Dubberke1
1Division of Infectious Diseases,  2Department of Medicine, and 3Department of Pathology and 
Immunology, Washington University School of Medicine, St. Louis, Missouri, USA
We report the case of a kidney transplantation patient on 
chronic immunosuppressive therapy presenting with subacute 
meningitis. The final diagnosis of cryptococcal meningitis was 
delayed due to 2 false-negative cryptococcal results on a molec-
ular diagnostic panel. Caution with such platforms in suspected 
cryptococcal meningitis is needed.
Keywords. cryptococcal meningitis; encephalitis; men-
ingitis; molecular diagnostic techniques; polymerase chain 
reaction. 
Worldwide, Cryptococcus is the most common cause of fungal 
meningitis [1]. Delayed diagnosis of cryptococcal meningitis 
is associated with increased morbidity and mortality [2, 3]. 
Culture remains the gold standard for diagnosis of cryptococcal 
disease [4]. The limitations of culture are that it can be time 
consuming and labor intensive. Cryptococcal antigen (CrAg) 
lateral flow assays are rapid, specific, and may be more sensitive 
than culture when the burden of organism is low [4]. However, 
in patients presenting with symptoms of meningo-encephali-
tis, the causative organism is frequently not clinically apparent, 
there can be a large potential differential diagnosis requiring 
consideration, and there may be limited available cerebral spinal 
fluid (CSF) for testing. Efforts have been made in recent years 
to develop assays that would allow testing for a wide variety 
of pathogens associated with meningo-encephalitis in a short 
time frame and using small volumes of CSF. The FilmArray 
Meningitis/Encephalitis (ME) Panel (BioFire Diagnostics, Salt 
Lake City, UT) uses multiplex polymerase chain reaction (PCR) 
to test for 14 targets using just 200 µL of CSF with a reported 
hands-on time of 2 minutes and a turnaround time of approxi-
mately 1 hour [5]. As with all diagnostic tools, it is paramount 
that clinicians interpret results from PCR panels such as these 
in the context of the patient’s clinical presentation, and that they 
are aware of any pitfalls associated with such tests. Herein we 
report a case where the clinical outcome for the patient was neg-
atively impacted by the use of a PCR panel.
CASE REPORT
A 54-year-old woman sought medical attention for a head-
ache of 4  days’ duration, associated with nausea but without 
focal neurological signs. She had undergone deceased donor 
kidney transplantation for lupus nephritis–induced end-stage 
kidney disease 5 years previously and was receiving tacrolimus, 
mycophenolate mofetil (MMF), and prednisolone as immuno-
suppressive therapy. She was diagnosed with migraine and pre-
scribed a short course of hydrocodone. She did not have a past 
history of migraines. Over the proceeding month, she presented 
with persistent headache twice more to her primary care pro-
vider, and on 3 occasions to the emergency department where 
she underwent computed tomography and magnetic resonance 
imaging (MRI) of the brain, both of which were within normal 
limits.
Two months after the headache onset, the patient presented 
to her local hospital with headaches, nausea and vomiting, and 
fever. She was commenced on broad-spectrum antimicrobial 
therapy. Her CSF revealed a white cell count (WCC) of 145 
cells/cm3 (27% neutrophils, 63% lymphocytes, 10% mono-
cytes), glucose of 36 mg/dl, and protein of 72 mg/dl. Gram stain 
and routine bacterial cultures were negative. Fungal and myco-
bacterial cultures were not performed. A FilmArray Meningitis/
Encephalitis (ME) Panel detected human herpes virus 6 (HHV-6) 
but was negative for the remaining 13 components tested for by 
the panel (Escherichia coli K1, Haemophilus influenzae, Listeria 
monocytogenes, Neisseria meningitidis, Streptococcus agalactiae, 
Streptococcus pneumoniae, cytomegalovirus, enterovirus, her-
pes simplex virus 1 and 2, human parechovirus, varicella zoster 
virus, and Cryptococcus neoformans/gattii). Antimicrobial ther-
apy was discontinued, and the patient was discharged on anal-
gesia with symptoms attributed to HHV6 infection.
In the weeks that followed, the patient continued to clinic-
ally deteriorate, developing difficulty with her gait and fecal 
incontinence. New onset of abdominal pain, now 3  months 
after the headache onset, prompted her to once again seek med-
ical assessment. The patient was readmitted, and her work-up 
revealed acute pancreatitis of unknown etiology, with a lipase of 
18 800 units/L. At this time, MMF was held and she continued 
on tacrolimus and prednisolone immunosuppression. On day 
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11 of her admission, the patient became febrile to 38.6°C. Blood 
cultures were obtained, and she was initiated on empiric mer-
openem; subsequently, linezolid and micafungin were added. 
On day 19, after a fall, she was noted to be encephalopathic 
with psychomotor slowing, which triggered a repeat neurolog-
ical workup. A brain MRI did not reveal any acute intracranial 
processes. Lumbar puncture (LP) revealed a WCC count of 320 
cells/cm3 (58% neutrophils, 37% lymphocytes), a glucose of 
8  mg/dl, and protein of 121  mg/dl. No opening pressure was 
recorded. Again, a FilmArray ME Panel was performed, but it 
was negative for all pathogens included in the panel. CSF bac-
terial culture was negative.
On hospital day 20, the patient was transferred to a tertiary 
care academic center. On arrival, she was afebrile but remained 
encephalopathic, with altered speech. She intermittently fol-
lowed simple commands and had evidence of meningismus. 
A  high-volume (10  mL of CSF) LP was performed, and the 
IMMY cryptococcal antigen lateral flow assay was positive at 
a titer of 1:20. Her serum CrAg was also positive at 1:10. The 
patient was initiated on liposomal amphotericin and flucytosine 
for management of cryptococcal meningitis. CSF from the LP 
performed prior to transfer was obtained and was also found 
to be positive at a titer of 1:40. All cultures, including blood 
and CSF, were negative. The patient’s symptoms improved on 
liposomal amphotericin and flucytosine, and she was ultimately 
discharged 3 weeks later on fluconazole.
DISCUSSION
This case highlights some important issues associated with the 
use of PCR panels such as the FilmArray ME Panel in clin-
ical practice. The clinical assay performance of the FilmArray 
ME Panel was assessed in a multicenter study that examined 
1560 residual CSF samples from patients undergoing lumbar 
puncture at 11 sites across the United States [6]. In this study, 
the results from the FilmArray ME Panel were compared with 
what was considered by the study team to be an appropriate 
comparator method. The comparator was CSF culture for the 
bacteria and bidirectional PCR sequencing for the viruses and 
fungi included in the panel. The sensitivity for Cryptococcal 
neoformans/gattii was reported at 100% (1/1) and was included 
in the overall assay sensitivity despite being calculated from 
a single positive specimen. Specificity for Cryptococcus spp. 
was reported as 99.7% (1555/1559). Of note, the comparator 
method for Cryptococcus in this study was PCR and not culture 
or CrAg testing. The investigators reviewed the records of the 
4 patients who had positive results by the FilmArray ME Panel 
but negative results by the comparator PCR and determined 
that 2 were falsely negative by the comparator, and thus true 
positives detected by the FilmArray ME Panel. Not included in 
the published results but included in the FilmArray ME Panel 
package insert were comparisons with the test results of the 
clinical labs. The FilmArray ME Panel was positive for 1 of the 
8 (12.5%) specimens positive for CrAg, and positive for 2 of 3 
(66.7%) that were culture positive. Of the 7 that were positive 
for CrAg but negative by the FilmArray ME Panel, all patients 
were on antifungals at the time of specimen collection or had a 
history of Cryptococcal meningitis.
Interestingly, a smaller preclinical study of a 16-target 
FilmArray ME Panel highlighted the importance of an appro-
priate comparator test [7]. When the 16-target assay was 
performed on 342 stored CSF specimens, 8 of 14 (57%) CrAg-
positive specimens were positive by the FilmArray ME panel, 
with 1 specimen that was CrAg negative/FilmArray positive 
also testing positive by sequencing. The false-negative results 
came from specimens with relatively low CrAg titers and/
or high PCR crossing thresholds, and therefore were likely 
related to low burden of disease. This may also explain why the 
FilmArray ME Panel performed well in subjects with first pres-
entations of cryptococcal meningitis in a study performed in 
sub-Saharan Africa where the median quantitative culture was 
8950 CFU/mL (IQR, 118–113  500 CFU/mL) [8]. Decreased 
sensitivity was observed in this study on follow-up CSF spec-
imens obtained from therapeutic lumbar puncture in patients 
receiving appropriate antifungal therapy and presumably hav-
ing lower fungal burdens. In those with positive cryptococcal 
cultures and quantitative colony count <100 CFU/mL, the sen-
sitivity was 50% (6/12).
In the case reported herein, the patient was treated with the 
calcineurin inhibitor tacrolimus, a class of drugs known to have 
in vitro antifungal activity. In solid organ transplant recipients, 
tacrolimus has previously been associated with lower mortality 
rates in the setting of cryptococcal infection [9]. It is therefore 
possible that tacrolimus therapy may have contributed to the 
lower CrAg titers in this case, and potentially to the false-neg-
ative cryptococcal result obtained on the FilmArray ME Panel, 
although there are no specific data available in relation to the 
latter. It is also noteworthy that while echinocandins generally 
have little activity against Cryptococcus neoformans alone, in 
vitro synergy between caspofungin and tacrolimus has been 
reported [10].
To our knowledge, this is the first reported case of a patient 
whose clinical outcome was negatively impacted by a false-neg-
ative cryptococcal PCR on the FilmArray ME panel. The patient 
had known risk factors for cryptococcal meningitis with a typ-
ical clinical presentation and CSF profile, which ought to have 
prompted a more thorough investigation. This case serves to 
highlight to clinicians the importance of understanding the 
diagnostic accuracy of tests performed in order to ensure that 
they are appropriately interpreted, particularly in the setting 
where a sensitive, cheap, and easily performed alternative diag-
nostic test exists. Compared with culture and CrAg, the sensi-
tivity of the FilmArray ME Panel for Cryptococcus in the United 
States appears to be in the mid-60% range at best. Patients with 
a low burden of disease or who are already on antifungals are 
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more likely to have a false-negative FilmArray ME Panel for 
Cryptococcus. This case also highlights the potential downside 
of testing for a multitude of pathogens, several of which may 
not be clinically relevant. In this case, the initial FilmArray ME 
panel performed was positive for HHV6, and the patient symp-
toms and abnormal CSF profile were initially inappropriately 
attributed to this, and possibly contributed to the delay in the 
diagnosis of this patient’s cryptococcal meningitis.
In conclusion, clinicians should be aware that a negative 
cryptococcal result on this platform does not rule out crypto-
coccal meningitis, and standard assessment with CrAg and 
culture should be performed when the clinical scenario is con-
sistent with cryptococcal infection.
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